Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » siRNA

siRNA

Jun 26, 2020

Science Papers Report on Chromatin Fiber Sequencing, Mutations Linked to Risk of Cardiovascular Events on Osteoporosis Drug, More

In Science this week: Fiber-seq method to examine regulatory architecture, mutations in SOST associated with osteoporosis drug-linked cardiovascular events, and more.

 

Oct 23, 2019

Biotech Startup Korro Bio Uses Temporary Gene Editing Technology to Create Therapeutics

Premium

The company's platform is based on nucleotide deamination, a process that occurs naturally in cells and doesn't create a permanent edit in the genome.

Jan 29, 2019

This Week in PNAS: Jan 29, 2019

In PNAS this week: Fanconi anemia protein role in ribosome biogenesis, small interfering RNAs in A. thaliana seeds development, and more.

Aug 31, 2017

Cowen Initiates Coverage of Horizon Discovery at Outperform

The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.

Jul 08, 2015

Startup Persomics Aims to Launch Mini RNAi Screening Tech by Year-End

Premium

With optimization work currently being done with beta testers, the company is negotiating with companies to provide their siRNA library content on its plates.

Aug 14, 2014

IP Update: Recent Patents Awarded to Alnylam, Tekmira, Polyplus, and More

Premium

Title: RNA Interference Modulators of Hedgehog Signaling and Uses Thereof
Patent Number: 8,802,639
Filed: March 24, 2005

Jun 26, 2014

InteRNA, Collaborators Publish Details of siRNA, microRNA Delivery Technology

Premium

NEW YORK (GenomeWeb) – InteRNA Technologies and academic collaborators this month reported details of an siRNA-delivery technology capable of specifically targeting tumor vasculature, along with in vitro data demonstrating its ability to carry siRNAs into human umbilical vein endothelial

Jan 09, 2014

Dicerna Poised to Become Second RNAi Drug Firm to Complete IPO

Premium

Should Dicerna Pharmaceuticals complete its planned initial public offering, the company would be the first RNAi drug developer to go public since Alnylam Pharmaceuticals did so in 2004.

Jan 07, 2014

Horizon, AstraZeneca Collaborate on Genotypes for Synthetic Lethality

NEW YORK (GenomeWeb News) – Horizon Discovery today announced a research collaboration and licensing deal with AstraZeneca to interrogate oncology-relevant genotypes in order to identify and validate new drug targets.

Dec 12, 2013

Life Tech Allows Release of Full siRNA Sequence Data from NIH RNAi Screens

Premium

This article has been updated to include information about Life Technologies' spokesperson.

Pages

The Scan

This Time, Novavax

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Shortened Visas for Some Students

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

New York's Own Review

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Science Papers Examine Y Chromosomes of Archaic Humans, Schistosomiasis Therapeutic Targets

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.